Issue:3 Citation: Sachin S

Sachin Shinde, Amol Deshmukh, Pallavi Nagadkar, Kundan Tiwari
2015 Shinde et al. Ijppr.Human   unpublished
The past decade has seen an exponential increase of novel therapeutic modalities for a variety of rheumatic disorders, including gout. Gout is the common inflammatory arthritis in an elderly population and can be challenging because its typical appearances are more common in elderly. The management of hyperuricemia in elderly with gout requires special consideration in terms of co-medication, contraindications and risk of adverse reactions. So the Urate-lowering agents including allopurinol and
more » ... ing allopurinol and uricosuric agents are also used sensibly in the elderly. The novel therapeutic agent recently approved by USFDA for the treatment of rheumatic disorders in gout is Febuxostat, a nonpurine selective xanthine oxidase inhibitor. This review presents its pharmacokinetics and pharmacodynamics, efficacy and safety profile and its usefulness in gout patients. Febuxostat can be used in patients with mild-to-moderate renal or hepatic impairment.